Keywords: USA, FDA, Gilead, Aztreonam, Cystic fibrosis

FDA advisory committee backs safety and efficacy of Gilead’s aztreonam for cystic fibrosis

Article | 11 December 2009

Print This

The Anti-Infective Drugs Advisory Committee of the US Food and Drug Administration (FDA) has recommended that Gilead Sciences’ aztreonam for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in